|
IL139960A0
(en)
|
1998-06-17 |
2002-02-10 |
Eisai Co Ltd |
Macrocylic analogs and methods of their use and preparation
|
|
US8097648B2
(en)
*
|
1998-06-17 |
2012-01-17 |
Eisai R&D Management Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
US6653341B1
(en)
|
1998-06-17 |
2003-11-25 |
Eisai Co., Ltd. |
Methods and compositions for use in treating cancer
|
|
DE10037310A1
(de)
|
2000-07-28 |
2002-02-07 |
Asta Medica Ag |
Neue Indolderivate und deren Verwendung als Arzneimittel
|
|
EP1531846A4
(en)
*
|
2002-02-27 |
2006-04-19 |
Us Gov Health & Human Serv |
Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
|
|
AU2003228354B8
(en)
|
2002-03-22 |
2010-03-04 |
Eisai R&D Management Co., Ltd. |
Hemiasterlin derivatives and uses thereof in the treatment of cancer
|
|
US20050075395A1
(en)
*
|
2003-05-28 |
2005-04-07 |
Gary Gordon |
Continuous dosing regimen
|
|
CA2526385C
(en)
*
|
2003-05-29 |
2008-07-22 |
Abbott Laboratories |
Continuous dosing regimen with abt-751
|
|
US20070196418A1
(en)
*
|
2003-07-29 |
2007-08-23 |
Michael Lewis |
Drug delivery methods and devices
|
|
PL2522663T3
(pl)
*
|
2004-06-03 |
2015-08-31 |
Eisai R&D Man Co Ltd |
Produkty pośrednie do otrzymywania halichondryny B
|
|
CN1993342A
(zh)
*
|
2004-06-03 |
2007-07-04 |
卫材株式会社 |
用于制备软海绵素b的中间体
|
|
US20060045846A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Horstmann Thomas E |
Reagents and methods for labeling terminal olefins
|
|
WO2006076100A2
(en)
*
|
2004-12-09 |
2006-07-20 |
Eisai Co. Ltd. |
Tubulin isotype screening in cancer therapy using halichondrin b analogs
|
|
EP2578576B9
(en)
|
2007-10-03 |
2016-09-14 |
Eisai R&D Management Co., Ltd. |
Intermediates for the synthesis of halichondrin B analogs
|
|
US8598373B2
(en)
*
|
2008-04-04 |
2013-12-03 |
Eisai R&D Management Co., Ltd. |
Halichondrin B analogs
|
|
RU2476216C1
(ru)
*
|
2009-03-30 |
2013-02-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Липосомальная композиция
|
|
KR101495951B1
(ko)
|
2009-03-30 |
2015-02-25 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
리포솜 조성물
|
|
EP2415464B1
(en)
|
2009-03-30 |
2017-05-10 |
Eisai R&D Management Co., Ltd. |
Method for producing liposome composition
|
|
US8765974B2
(en)
*
|
2009-04-14 |
2014-07-01 |
Nissan Chemical Industries, Ltd. |
Method for producing tetrahydropyran compound and intermediate thereof
|
|
SG182612A1
(en)
|
2010-01-26 |
2012-08-30 |
Eisai R&D Man Co Ltd |
Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
|
|
EP2686441B1
(en)
|
2011-03-18 |
2019-05-08 |
Eisai R&D Management Co., Ltd. |
Methods and uses for predicting response to eribulin
|
|
WO2012147900A1
(en)
|
2011-04-28 |
2012-11-01 |
Eisai R&D Management Co., Ltd. |
Microreactor process for halichondrin b analog synthesis
|
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
|
AU2012344697A1
(en)
|
2011-11-30 |
2014-07-10 |
Alphora Research Inc. |
Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
|
|
JP2015501818A
(ja)
|
2011-12-16 |
2015-01-19 |
アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． |
３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
|
|
IN2014MN01521A
(enExample)
*
|
2011-12-29 |
2015-05-01 |
Alphora Res Inc |
|
|
WO2013142999A1
(en)
*
|
2012-03-30 |
2013-10-03 |
Alphora Research Inc. |
Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
|
|
RU2689977C2
(ru)
|
2012-12-04 |
2019-05-30 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Применение эрибулина для лечения рака молочной железы
|
|
CA2909209A1
(en)
|
2013-05-15 |
2014-11-20 |
Alphora Research Inc. |
3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
|
|
KR102265952B1
(ko)
|
2013-06-26 |
2021-06-16 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
|
|
JP6511613B2
(ja)
*
|
2013-07-03 |
2019-05-15 |
サンド・アクチエンゲゼルシヤフト |
ハリコンドリンＢの大環状Ｃ１−ケト類似体の製造のための合成方法及び該方法に有用な中間体、例えば−ＳＯ２−（ｐ−トリル）基を含有する中間体
|
|
CN103483352A
(zh)
*
|
2013-10-18 |
2014-01-01 |
李友香 |
抗肿瘤的药用原料药
|
|
HUE049387T2
(hu)
|
2013-11-04 |
2020-09-28 |
Eisai R&D Man Co Ltd |
A halichondrin B analógjainak szintézisében hasznos makrociklizációs reakciók és köztitermékek
|
|
SG11201604545XA
(en)
|
2013-12-06 |
2016-07-28 |
Eisai R&D Man Co Ltd |
Methods useful in the synthesis of halichondrin b analogs
|
|
CN104860978A
(zh)
*
|
2014-02-20 |
2015-08-26 |
正大天晴药业集团股份有限公司 |
软海绵素b类似物的合成中间体
|
|
TW201617326A
(zh)
*
|
2014-03-06 |
2016-05-16 |
Ａｌｐｈｏｒａ研發股份有限公司 |
（ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
|
|
KR20170039096A
(ko)
*
|
2014-05-28 |
2017-04-10 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
암의 치료에 있어서 에리불린의 용도
|
|
JP2017520586A
(ja)
|
2014-06-30 |
2017-07-27 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ハリコンドリン類似体の合成およびその使用
|
|
IL302218B2
(en)
|
2014-08-28 |
2024-10-01 |
Eisai R&D Man Co Ltd |
Methods for manufacturing high-purity lenvatinib and its derivatives
|
|
WO2016038624A1
(en)
|
2014-09-09 |
2016-03-17 |
Cipla Limited |
"process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof"
|
|
CN105713031B
(zh)
*
|
2014-12-05 |
2021-05-07 |
正大天晴药业集团股份有限公司 |
一种用于制备艾日布林的中间体及其制备方法
|
|
JP6792546B2
(ja)
|
2015-02-25 |
2020-11-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体の苦味抑制方法
|
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
|
AU2016226157B2
(en)
|
2015-03-04 |
2022-01-27 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and eribulin for treating cancer
|
|
WO2016176560A1
(en)
|
2015-04-30 |
2016-11-03 |
President And Fellows Of Harvard College |
Chromium-mediated coupling and application to the synthesis of halichondrins
|
|
KR102743950B1
(ko)
|
2015-05-07 |
2024-12-18 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
할리콘드린 마크롤라이드의 합성에 유용한 마크로고리화 반응 및 중간체 및 기타 단편
|
|
WO2016182850A1
(en)
|
2015-05-08 |
2016-11-17 |
Albany Molecular Research, Inc. |
Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
|
|
EP3311841B1
(en)
|
2015-06-16 |
2021-07-28 |
PRISM BioLab Co., Ltd. |
Anticancer agent
|
|
CN108135894B
(zh)
|
2015-08-20 |
2021-02-19 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
|
JP6786610B2
(ja)
*
|
2016-02-12 |
2020-11-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
エリブリンの合成における中間体および関連する合成方法
|
|
EP3449921B1
(en)
|
2016-04-28 |
2023-05-31 |
Eisai R&D Management Co., Ltd. |
Eribulin for inhibiting tumor growth
|
|
BR112018074287A2
(pt)
|
2016-05-26 |
2019-06-18 |
Dr Reddys Laboratories Ltd |
processo para preparação de eribulina e intermediários da mesma
|
|
MX390072B
(es)
|
2016-06-30 |
2025-03-20 |
Eisai R&D Man Co Ltd |
Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
|
|
WO2018071792A1
(en)
|
2016-10-14 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
|
JP6978758B2
(ja)
|
2016-11-11 |
2021-12-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
パラジウム媒介ケトール化
|
|
JP2020511404A
(ja)
*
|
2016-11-23 |
2020-04-16 |
ドクター レディズ ラボラトリーズ リミテッド |
エリブリン及びその中間体の調製方法
|
|
KR101991710B1
(ko)
|
2017-12-14 |
2019-06-21 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
|
ES2932832T3
(es)
|
2017-01-02 |
2023-01-26 |
Yonsung Fine Chemical Co Ltd |
Intermedio de producción de mesilato de eribulina, y método para producir el mismo
|
|
KR101880939B1
(ko)
|
2017-01-02 |
2018-08-17 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
|
CN108341828B
(zh)
*
|
2017-01-24 |
2021-04-06 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
|
CN108341738B
(zh)
*
|
2017-01-24 |
2022-10-21 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的方法及其中间体
|
|
RU2750539C2
(ru)
|
2017-02-08 |
2021-06-29 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Фармацевтическая композиция для лечения опухоли
|
|
HRP20221385T1
(hr)
|
2017-04-05 |
2023-01-06 |
President And Fellows Of Harvard College |
Makrociklički spoj i njegova uporaba
|
|
US9938288B1
(en)
|
2017-04-05 |
2018-04-10 |
President And Fellows Of Harvard College |
Macrocyclic compound and uses thereof
|
|
AU2018269996A1
(en)
|
2017-05-16 |
2019-11-21 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
US11548898B2
(en)
|
2017-07-06 |
2023-01-10 |
President And Fellows Of Harvard College |
Synthesis of halichondrins
|
|
US11498892B2
(en)
|
2017-07-06 |
2022-11-15 |
President And Fellows Of Harvard College |
Fe/Cu-mediated ketone synthesis
|
|
US20190046513A1
(en)
|
2017-08-10 |
2019-02-14 |
Huya Bioscience International, Llc |
Combination therapies of hdac inhibitors and tubulin inhibitors
|
|
CN109694379B
(zh)
*
|
2017-10-24 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
用于制备艾日布林的中间体及其制备方法
|
|
KR102177992B1
(ko)
*
|
2017-11-09 |
2020-11-12 |
연성정밀화학(주) |
에리불린 메실산염의 제조 중간체 및 그의 제조방법
|
|
EP3710454B1
(en)
|
2017-11-15 |
2024-01-03 |
President And Fellows Of Harvard College |
Macrocyclic compounds and uses thereof
|
|
US11419856B2
(en)
|
2017-11-20 |
2022-08-23 |
Basilea Pharmaceutica International AG |
Pharmaceutical combinations for use in the treatment of neoplastic diseases
|
|
WO2019102490A1
(en)
|
2017-11-21 |
2019-05-31 |
Natco Pharma Limited |
Intermediates for the preparation of eribulin thereof
|
|
KR102799793B1
(ko)
|
2018-01-03 |
2025-04-25 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 화합물
|
|
WO2019211877A1
(en)
|
2018-05-03 |
2019-11-07 |
Cipla Limited |
Process for the preparation of macrocyclic ketone analogs of halichondrin b
|
|
WO2020008382A1
(en)
*
|
2018-07-04 |
2020-01-09 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of eribulin and intermediates thereof
|
|
CN112437775A
(zh)
*
|
2018-07-20 |
2021-03-02 |
雷迪博士实验室有限公司 |
用于制备艾日布林及其中间体的纯化方法
|
|
EP3864011A4
(en)
*
|
2018-10-09 |
2022-06-29 |
Dr. Reddy's Laboratories Ltd. |
Process for preparation of eribulin and intermediates thereof
|
|
US20220089607A1
(en)
*
|
2018-11-28 |
2022-03-24 |
Natco Pharma Limited |
Process for the preparation of high pure eribulin and its mesylate salt
|
|
CA3124412A1
(en)
|
2018-12-20 |
2020-06-25 |
Auransa Inc. |
Analogues of pentamidine and uses therefor
|
|
US11447499B2
(en)
|
2019-06-14 |
2022-09-20 |
Rk Pharma Inc. |
Process for the preparation of eribulin mesylate intermediate
|
|
WO2020255164A1
(en)
|
2019-06-21 |
2020-12-24 |
Council Of Scientific And Industrial Research |
A chemo-enzymatic process for the preparation of homopropargylic alcohol
|
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
US12036204B2
(en)
|
2019-07-26 |
2024-07-16 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
|
PH12022551036A1
(en)
|
2019-11-07 |
2023-05-29 |
Eisai R&D Man Co Ltd |
Anti-mesothelin eribulin antibody-drug conjugates and methods of use
|
|
CN113135876B
(zh)
*
|
2020-01-16 |
2024-05-17 |
南通诺泰生物医药技术有限公司 |
艾日布林及其中间体的制备方法
|
|
WO2021148003A1
(zh)
*
|
2020-01-22 |
2021-07-29 |
上海森辉医药有限公司 |
艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
|
|
KR102377262B1
(ko)
|
2020-05-11 |
2022-03-22 |
연성정밀화학(주) |
결정성 에리불린 염
|
|
IL279168B
(en)
*
|
2020-12-02 |
2022-04-01 |
Finetech Pharmaceutical Ltd |
A process for the preparation of eribulin
|
|
CN113354659B
(zh)
|
2021-06-08 |
2022-04-08 |
江苏慧聚药业股份有限公司 |
甲磺酸艾日布林的合成
|
|
EP4374879A1
(en)
*
|
2021-07-22 |
2024-05-29 |
Shanghai Senhui Medicine Co., Ltd. |
Drug conjugate of eribulin derivative
|
|
WO2023212746A2
(en)
*
|
2022-04-30 |
2023-11-02 |
William Marsh Rice University |
A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
|
|
TW202434308A
(zh)
*
|
2023-01-17 |
2024-09-01 |
大陸商成都百利多特生物藥業有限責任公司 |
一種艾日布林類藥物的偶聯物
|
|
CN118834221B
(zh)
*
|
2023-08-08 |
2025-10-21 |
浙江星月药物科技有限公司 |
一种软海绵素b类似物
|
|
TW202518024A
(zh)
|
2023-10-13 |
2025-05-01 |
日商衛材R&D企管股份有限公司 |
抗體－藥物軛合物代謝物
|
|
WO2025106586A1
(en)
*
|
2023-11-13 |
2025-05-22 |
Luxvitae Therapeutics Inc. |
Macrocyclic ketone compounds and applications thereof
|
|
WO2025228172A1
(zh)
*
|
2024-04-28 |
2025-11-06 |
上海拓济医药有限责任公司 |
艾日布林衍生物及其抗体药物偶联物和医药用途
|